Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.

 

Important Public Notice: ANCC Magnet Recognition Program® - Site Visit through November 4, 2022. Click here to learn more.

MENU

Fox Chase Cancer Center’s Suzanne Miller Takes Lead for Special Edition of Translational Behavioral Medicine

November 30, 2021

Dr. Suzanne M. Miller, Cancer Prevention and Control Program professorDr. Suzanne M. Miller, Cancer Prevention and Control Program professor

PHILADELPHIA (November 30, 2021)—Suzanne M. Miller, PhD, a professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, has spearheaded a recent special edition of Translational Behavioral Medicine published today that summarizes several major lines of cancer prevention and control research and outlines future directions.

“This edition is a convergence of 50 years of the National Cancer Act and 10 years of the journal. The National Cancer Institute, part of the National Institutes of Health, and the journal came together to highlight where we are, how far we’ve come in terms of cancer prevention and control,” said Miller, who has been editor-in-chief of the journal since 2015.

The newest edition of Translational Behavioral Medicine: Practice, Policy, Research, “Cancer Prevention and Control for a New Decade,” features twelve articles that explore the current state of scientific progress in areas of cancer population sciences research.

“The articles focus on the authors’ perspectives on the future of research related to their area of expertise. The articles also co-address research related to two or more stages of the cancer control continuum, from etiology to prevention and detection, to diagnosis and treatment and survivorship, to end-of-life care,” said Miller.

“Our goal is to significantly impact the mission and vision of cancer prevention and control research, practice, and policy over the next decade. In doing so, this issue seeks to inspire and shepherd the next generation of scholars, highlighted by Translational Behavioral Medicine’s commitment that most articles include one or more early-career behavioral medicine scientist co-authors,” she said.

The special edition was developed as a result of collaborations among researchers from The Feinstein Institutes for Medical Research and the Division of Cancer Control and Population Sciences at the National Cancer Institute. The contributions in this special issue are divided into five subsections covering important topics such as impacts on population health, behavioral change strategies, and new methods for moving forward.

“When I came to the journal, there were virtually no cancer pieces in it. I made it my mission to make this a forum where cancer prevention and control researchers wanted to publish. This issue really culminates almost a decade of our becoming a leader in publishing great science that has an impact on population and policy,” said Miller.

“Cancer remains one of our greatest health concerns in the United States and around the world. We want to highlight that what the field needs right now, more than ever, is to continue its strong leadership and advocacy efforts to inform the agenda for U.S. cancer research and cancer policy going forward,” she said.

The Society of Behavioral Medicine is an organization of clinicians, educators, and researchers. It seeks to promote the study of the interactions of behavior with biology and the environment and apply that knowledge to improve the health and well-being of individuals, families, communities, and populations. Translational Behavioral Medicine is published by Oxford University Press on behalf of the Society for Behavioral Medicine

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Connect with Fox Chase